Characteristics and Echogenicity of Clinical Ultrasound Contrast Agents: An In Vitro and In Vivo Comparison Study
| Autor: | Emmanuel Gaud, Thierry Bettinger, Jean-Marc Hyvelin, Maria Costa, Alexandre Helbert, Peter Frinking, Philippe Bussat |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Contrast enhancement Radiological and Ultrasound Technology business.industry Ultrasound Echogenicity 030204 cardiovascular system & hematology 030218 nuclear medicine & medical imaging 03 medical and health sciences Clinical ultrasound 0302 clinical medicine In vivo medicine Medical imaging Comparison study Radiology Nuclear Medicine and imaging Radiology business Nuclear medicine Preclinical imaging |
| Zdroj: | Journal of Ultrasound in Medicine. 36:941-953 |
| ISSN: | 0278-4297 |
| DOI: | 10.7863/ultra.16.04059 |
| Popis: | Objectives To compare physicochemical characteristics and in vitro and in vivo contrast-enhanced ultrasound imaging performance of 3 commercially available ultrasound contrast agents: SonoVue (Bracco Imaging SpA, Colleretto Giacosa, Italy; also marketed as Lumason in the USA), Definity (Lantheus Medical Imaging, North Billerica, MA) and Optison (GE Healthcare AS, Oslo, Norway). Methods Physicochemical characteristics were measured with a Multisizer Coulter Counter (Beckman Coulter, Fullerton, CA). Two ultrasound systems (Aplio 500; Toshiba Medical Systems Corp, Tochigi-ken, Japan; and Logiq E9; GE Healthcare, Little Chalfont, England) were used with different transducers. Contrast enhancement was measured in vitro by dose-ranging measurements using a custom-built beaker setup; in vivo imaging performances were compared in pigs (heart and liver) and rabbits (liver). Quantitative analyses were performed with VueBox quantification software (Bracco Suisse SA, Plan-les-Ouates, Switzerland). Results Measured physicochemical characteristics were in agreement with those provided by the manufacturers. In vitro data demonstrated that the performance of SonoVue was similar to or better than that of Definity but superior to Optison (normalized scattered power 2- to 10-fold higher with SonoVue). Similar results were obtained in vivo, although the duration of enhancement in the pig heart was longer for SonoVue compared to Definity, and quantitative analysis revealed higher enhancement for SonoVue (1.5-fold increase). For liver imaging, SonoVue and Definity showed similar contrast enhancement and duration of enhancement, but compared to Optison, both peak enhancement and duration of enhancement were superior for SonoVue (up to 2-fold increase). Conclusions Imaging performance of SonoVue was similar to or slightly better than that of Definity, but it was superior to Optison for the conditions used in this study. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text